Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    34.657,35
    +318,03 (+0,93%)
     

  • Dow Jones

    39.512,84
    +125,08 (+0,32%)
     

  • Nasdaq

    16.340,87
    -5,40 (-0,03%)
     

  • Nikkei 225

    38.229,11
    +155,13 (+0,41%)
     

  • Petrolio

    78,20
    -1,06 (-1,34%)
     

  • Bitcoin EUR

    56.682,04
    +380,09 (+0,68%)
     

  • CMC Crypto 200

    1.265,80
    -92,20 (-6,79%)
     

  • Oro

    2.366,90
    +26,60 (+1,14%)
     

  • EUR/USD

    1,0772
    -0,0012 (-0,11%)
     

  • S&P 500

    5.222,68
    +8,60 (+0,16%)
     

  • HANG SENG

    18.963,68
    +425,87 (+2,30%)
     

  • Euro Stoxx 50

    5.085,08
    +30,67 (+0,61%)
     

  • EUR/GBP

    0,8598
    -0,0010 (-0,11%)
     

  • EUR/CHF

    0,9760
    -0,0005 (-0,05%)
     

  • EUR/CAD

    1,4724
    -0,0020 (-0,14%)
     

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

Corvus Pharmaceuticals, Inc.
·1 minuto per la lettura
Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc.

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

BURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results.

The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.

ANNUNCIO PUBBLICITARIO

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib (CPI-818), an investigational, oral, small molecule drug that selectively inhibits ITK and is in a mid-stage clinical trial for patients with T cell lymphoma. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com